GlassScriptPhysician profile
Joseph D Dunaway
NPI 1225024482
$3,869.86
in general payments reported to CMS, 2019-2025
27 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $583 · 2024: $664 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.32 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $564.01 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Sunovion Pharmaceuticals INC. | $491.10 | 2019-2020 | |
| Novo Nordisk INC | $410.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $229.45 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $214.84 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.12 | 2024-2025 | Caplyta |
| Pfizer INC. | $160.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.87 | 2019-2024 | Jardiance |
| Allergan, INC. | $144.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.71 | 2019-2024 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $91.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.75 | 2019 | |
| Vanda Pharmaceuticals INC. | $77.32 | 2024-2025 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $55.56 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.31 | 2019 | |
| Glaxosmithkline, LLC. | $42.54 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $29.19 | 2019-2025 | Zepbound, Mounjaro |
| Mylan Specialty L.P. | $25.98 | 2019-2020 | |
| Almatica Pharma LLC | $25.09 | 2024 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $24.17 | 2019 | |
| Astellas Pharma US INC | $20.41 | 2019 | |
| Lundbeck LLC | $18.78 | 2025 | Rexulti |
| Amarin Pharma, INC. | $18.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.77 | 2019 | |
| Sumitomo Pharma America, INC. | $15.30 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dunaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.